Actively Recruiting
Improving Cervical Cancer Screening Coverage Among Underscreened Women Aged 50 to 74 in Switzerland Using HPV Self-sampling Strategies Breast Cancer-Related Approach for Increasing Cervical Cancer Screening
Led by Jessica Di Vincenzo Sormani · Updated on 2025-12-22
4500
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
J
Jessica Di Vincenzo Sormani
Lead Sponsor
U
University Hospital, Geneva
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating ways to increase cervical cancer screening participation among women aged 50 to 74 in Switzerland who have not been screened in the past three years. This randomized trial compares two approaches: one group receives an awareness letter about cervical cancer screening, and another group receives a free vaginal self-sampling kit for human papillomavirus (HPV) infection. The study also observes a control group recruited later to avoid influencing screening behavior. Women in the first intervention group will get an informative letter explaining the importance of screening, Swiss recommendations, and an invitation to schedule a screening appointment. The second group will receive a free home-based HPV self-sampling kit to collect a vaginal sample. The control group is observed without receiving these interventions during the initial study period. The trial will run starting in October 2025. Participants will be monitored for 12 months to measure their participation in cervical cancer screening. Researchers will also assess socio-demographic factors linked to screening, the choice between HPV testing and cytology, the prevalence of positive screening results, follow-up rates for those with positive tests, and how acceptable the screening methods are. The study will explore connections between cervical and breast cancer screening behaviors. Safety, compliance, and reasons for non-participation will also be evaluated.
CONDITIONS
Brief Title
Breast Cancer-Related Approach for Increasing Cervical Cancer Screening
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women receiving Breast Cancer Screening invitation letters in selected Swiss regions
- Aged 50 to 74 years old
- Not screened for cervical cancer in the past three years
- Speak one of the study languages: French, German, Italian, English, Spanish, or Portuguese
You will not qualify if you...
- Prior cervical cancer diagnosis
- History of hysterectomy
- Do not consent to participate
- Incapable of judgment or under legal guardianship
- Currently pregnant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - 12 months
Participants receive either an awareness letter about cervical cancer screening or a home-based HPV self-sampling kit to perform at their convenience.
Participants follow the assigned screening strategy over 12 months with no required study visits
Duration - Up to 12 months after screening
Participants who screen positive complete follow-up procedures as recommended by healthcare providers.
Additional visits depending on screening results and follow-up care
Trial Site Locations
Total: 1 location
1
University Hospitals of Geneva
Geneva, Canton of Geneva, Switzerland, 1205
Actively Recruiting
Research Team
J
Jessica Di Vincenzo-Sormani, PhD
P
Patrick Petignat, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here